When considering the CHI3L2 expression of tumor cells and macrophages together, we found the overall survival time was higher in patients with dual-low CHI3L2 expression in TC and MC compared to those in patients with non-dual CHI3L2 expression and dual high expression in DIG (Figure 3G), but this difference is not statistically significant in LGG and GBM (Figures 3H, I). The gene discussed is CHI3L2; the disease is glioblastoma.